A review examines ADAR RNA editing in ALS and other brain disorders
Original source
ADAR-mediated RNA editing in CNS disorders: from pathogenic mechanisms to therapeutic opportunities. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
- Studied in
- Human, Animal
A review describes how changes in adenosine deaminases acting on RNA (ADAR) activity may be involved in amyotrophic lateral sclerosis (ALS) and other central nervous system disorders. It discusses possible treatment strategies, including small-molecule modulators and targeted RNA-editing tools. The review also highlights barriers such as off-target editing and difficulty delivering treatments across the blood-brain barrier.
Why this matters
The findings are relevant to researchers investigating molecular mechanisms and future treatment approaches for ALS. They do not establish that ADAR-based treatments work in people or change current ALS care.
Limitations and context
This is a review of existing evidence, not a new clinical or patient study. It covers several central nervous system disorders, and the source does not provide evidence that any ADAR-based approach has improved outcomes in people with ALS. The proposed strategies still face delivery, targeting and safety challenges.